Seeking Alpha

Elias Simpson

View as an RSS Feed
View Elias Simpson's Comments BY TICKER:
Latest  |  Highest rated
  • Vipshop +10.7% AH on Q1 beat, guidance; Dangdang +4% [View news story]
    Don't forget my Fireswirl.
    May 14 08:27 PM | Likes Like |Link to Comment
  • What's Hurting Biotechnology Stocks? [View article]
    Why do you pick on MNKD? There's a partnership in the works, plus a disruptive treatment for one of the fastest growing health epidemics in the world.
    May 13 12:36 PM | 4 Likes Like |Link to Comment
  • History Shows MannKind Has A Near Certain Chance Of Approval [View article]
    I think you are missing Actelion in your final chart. 10 yes votes out of 13 is 77%.
    Apr 2 09:44 AM | 3 Likes Like |Link to Comment
  • Significant Upcoming Catalysts For These Biotechs Should Provide Alpha Opportunity [View article]
    According to the American Diabetes Association website: "Only people with type 2 diabetes can use pills to manage their diabetes, people with type 1 diabetes must use insulin."

    Also, since we're speculating...Mann could be waiting for some bargaining leverage with a big pharma. Who knows?
    Feb 18 03:02 PM | Likes Like |Link to Comment
  • Supreme Court Case Will Not Postpone Abtech's First Contract Wins [View article]
    Last quarter they announced earnings on the fourth (November) for the next week. I was expecting something today. Perhaps folks are speculating that the company is delaying some bad news. I also have read that microcap stocks have been taking this pullback harder than other companies, which is of course always the case. Maybe this 30% just comes with the territory of being a thinly traded, under reported company.
    Feb 7 03:09 PM | Likes Like |Link to Comment
  • Puget Technologies: It's Not A 3D Printing Stock [View article]
    Thanks. I saw this ad and thought--there's a good idea for a little under cover work.
    Jan 16 01:01 PM | 2 Likes Like |Link to Comment
  • Chelsea Therapeutics: Primed For An Easy Double [View article]
    Indeed. What has changed since the FDA rejected the drug? The company has rearranged some data? You ought to really believe in the potential for this drug before you buy in. It will fall below $1 on bad news.

    BTW, Lindsay Rosenwald run Paramount Biopharm, which owns CHTP, has a record of picking drugs with somewhat novel previous applications. The fact that this was approved in 1989 in Japan means absolutely nothing to the FDA. It serves as a red flag to me. Just see what happened recently to another Paramount company, Coronado Bioscience (CNDO) whose drug (slip worm, actually) had been used successfully to treat Chron's disease.

    Good luck to you...
    Nov 26 04:31 PM | 1 Like Like |Link to Comment
  • GCVRZ Forum Archive  [View instapost]
    pushes SNY into the green for the day? maybe too early to tell the effect.
    Nov 13 04:02 PM | Likes Like |Link to Comment
  • Seeking Truth From Facts – Friday, November 08, 2013 [View instapost]
    AVEO, AVEO, people said the same thing about AVEO.
    Nov 8 04:35 PM | Likes Like |Link to Comment
  • Harvard Bioscience completes regenerative medicine device spin-off [View news story]
    idkmybffjill,

    it's not exactly a sell off. the capitalization value is less because the company no longer includes HART.

    considering the distribution of HART shares at 1:4, HART market cap should be worth 20% that of HBIO. Respectively, HBIO would be worth 20% less now than before.

    i am long--but wouldn't buy HBIO right now. statistically speaking, spinoffs do better than the parent company post-split.
    Nov 5 09:50 PM | Likes Like |Link to Comment
  • SunOpta: 2012 Recap And What's The Next Catalyst [View article]
    thanks for the article, i should say.

    just read the IPO deal for Mascoma was cancelled.

    more waiting for that value?
    Apr 5 10:39 PM | Likes Like |Link to Comment
  • SunOpta: 2012 Recap And What's The Next Catalyst [View article]
    Any idea what kind of notice will be given in advance of the sale of OPM? Couldn't one wait to see the deal before investing for this reason?
    Apr 5 10:31 PM | Likes Like |Link to Comment
  • Cooper's Warrants: Free Play On Leveraged Upside [View article]
    so those shares that don't sell at $43 will race to be sold off, driving prices back down, appx. 60% towards where it was before the offer ($36). By these numbers it would drop $4.20, to $38.80.

    is that how the proration factor would effect the price? with a smaller float, would it be reasonable to assume that the effect would be 20% less? so a drop of $3.36 to $39.64?
    Apr 5 02:49 PM | Likes Like |Link to Comment
  • Cooper's Warrants: Free Play On Leveraged Upside [View article]
    Wouldn't a smaller float mitigate a significant drop post-tender?

    I'm ignorant to this, but how would the proration factor effect stock price?

    -Thank you.
    Apr 5 01:35 PM | Likes Like |Link to Comment
  • Will Genworth Financial Triple? [View article]
    Who doesn't love a good old fashioned rate increase?
    Mar 13 06:25 PM | Likes Like |Link to Comment
COMMENTS STATS
38 Comments
21 Likes